

## Oxidative Stress in Schizophrenia: Pathogenetic and Therapeutic Implications

Jeffrey K. Yao<sup>1-3</sup> and Ravinder Reddy<sup>1,2</sup>

### Abstract

Over a century, a wide-ranging variety of pathophysiological models and causal hypotheses have been conceptualized for schizophrenia. One among these is the role for free radical-mediated pathology in schizophrenia, indicating impaired antioxidant defense system (AODS) and presence of oxidative stress in patients with schizophrenia. For the past two decades, the whole investigative domain of AODS and oxidative stress has broadened to include the wider AODS components, direct central nervous system assays of AODS, chemical imaging studies, proteomics, genetics of AODS, and, of importance to sufferers of schizophrenia, antioxidant therapeutics. These are some of the perspectives that are reviewed by several articles in this Forum. Overall, there has been growing recognition of the importance of oxidative stress in the pathophysiology of schizophrenia and in treatment-related side effects. The totality of the evidence from biochemistry, metabolomics, proteomics, genetics, and *in vivo* brain imaging points to the presence of multifarious abnormalities in the AODS and redox signaling in schizophrenia. *Antioxid. Redox Signal.* 15, 1999–2002.

**S**CHIZOPHRENIA IS STILL one of the most mysterious and costliest mental disorders in terms of human suffering and societal expenditure" (28). Since over a century that schizophrenia has been conceptualized there have been wide-ranging variety of pathophysiological models and causal hypotheses of schizophrenia (14). One among these is the role for free radical-mediated pathology in schizophrenia that was proposed more than half century ago (12). In the intervening decades there has been a steady stream of evidence demonstrating impaired antioxidant defense system (AODS) and the presence of oxidative stress in patients with schizophrenia (33). The earliest studies focused on the enzymatic components of the AODS, primarily superoxide dismutase (SOD) which has been discovered by McCord and Fridovich in 1968, and revolutionized the study of oxygen free radicals in biochemistry (1). Subsequent studies reported a variety of alterations in glutathione peroxidase (GSHPx) and catalase (CAT) levels (33). Prilipko and Lideman (21) were the first to report excess lipid peroxidation in patients with schizophrenia, proving that altered enzymatic AODS was indeed resulting in oxidative stress. The first, and critical, connection between peripheral indices of impaired AODS and central pathology in schizophrenia was the finding of inverse relations between peripheral GSHPx activity and cortical sulcal prominence on CT scan (5). As our understanding of the in-

terrelations of the components of the AODS enlarged, it was clear that examining one AODS enzyme in isolation may have limited value for elucidating the role of impaired AODS in neuropsychiatric disease processes, suggesting that the dynamic aspects of the AODS likely have more salience to understanding the pathophysiology of schizophrenia (23). In the following two decades the whole investigative domain of AODS and oxidative stress has broadened to include the wider AODS components, direct central nervous system assays of AODS, chemical imaging studies, proteomics, genetics of AODS and, of importance to sufferers of schizophrenia, antioxidant therapeutics. These are some of the perspectives that will be reviewed by several articles in this Forum.

This Forum includes a comprehensive review of the reactive oxygen species (ROS) and the AODS, including the perturbations of these systems in schizophrenia (31). Yao and Keshavan review systematically the evidence of alterations within the multiple domains of AODS and redox signaling, and relations of these systems to altered phospholipid/polyunsaturated fatty acids and immune dysfunction also seen in schizophrenia. The body of evidence yields a complex picture that shows pathological alterations in multiple pathways involved in balancing ROS and the AODS in patients with schizophrenia, both prior to treatment initiation and after long-term treatment. Indices of oxidative stress and AODS

<sup>1</sup>Medical Research Service, VA Pittsburgh Healthcare System, Pittsburgh, Pennsylvania.

<sup>2</sup>Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.

<sup>3</sup>Department of Pharmaceutical Sciences, University of Pittsburgh School of Pharmacy, Pittsburgh, Pennsylvania.

have been examined in peripheral samples (whole blood, plasma, serum, red blood cell membranes, platelets, and urine) and the central nervous system (postmortem brain and cerebrospinal fluid). These findings in patients with schizophrenia include decreased nonenzymatic antioxidants in plasma (albumin, uric acid, and ascorbic acid and vitamin E), and GSH deficits in prefrontal cortex *in vivo*, caudate region of postmortem brains, and in cerebrospinal fluid. Altered levels of scavenging antioxidant enzymes (SOD, GSHPx peroxidase, and catalase) have been reported for the past three decades. Most of these changes are in the direction that favors oxidative stress. More recently, there has been increasing interest in nitric oxide (NO) signaling. Yao *et al.* (32) provided the first evidence of an increased NO production in postmortem caudate nucleus from patients with schizophrenia. A variety of findings of plasma nitrite, serum NO, red blood cell NO, and platelets NO synthase activity, however, have been inconsistent. Further, alterations in the metabolism of several neurotransmitter systems can both contribute to, and be modified by oxidative stress (or membrane dysfunction).

The review also sheds light on homeostatic imbalance of AODS which has been examined for GSH redox coupling and purine catabolism. Both systems show alterations that would favor oxidative stress. The most direct evidence for oxidative injury in schizophrenia, however, comes from the findings of increased lipid peroxidation and protein modifications. Thus, the unchecked effects of free radicals can lead to structural and functional defects of cellular membranes. Such an imbalanced AODS may provide the basis for an increased release of specific cytokines as well as membrane abnormalities that have been reported in schizophrenia. There is ample evidence for the existence of membrane phospholipid and fatty acid defects in early course and chronic schizophrenia.

The incidence of schizophrenia is approximately 0.53 per 1000 population. Several environmental risk factors such as perinatal viral infections, obstetric trauma, and maternal malnutrition have been identified, as well as familial clustering (13, 24). The heritability for schizophrenia has been estimated at 60–80%, and complex segregation analyses have consistently rejected monogenic models in favor of polygenic inheritance (18). Hence, the gene mapping effort attempts to find genetic variants that explain all or a portion of the variance in a trait in a population. This can typically be attained in a family study setting ("linkage"), or through unrelated individuals ("association"). Like other genetically complex disorders, linkage studies in schizophrenia have been relatively unsuccessful. Later studies investigated "positional candidates," that is, genes localized to linked regions that are expressed in the brain and plausibly have a role in pathogenesis of schizophrenia, reviewed in this Forum by Chowdari *et al.* (8), yielding several positional candidates: Dysbindin (*DTNBP1*), Neuregulin 1 (*NRG1*), D-amino-acid oxidase (*DAO*), and G72 (also named D-amino acid oxidase activator [*DAOA*]) (26).

One of the more exciting developments has been the introduction of gene mapping of the numerous genes that encode antioxidant factors (9). Genetic association studies have been conducted with polymorphisms in some of these genes, reviewed by Chowdari *et al.* (8). They review GSH synthesis genes, GSH-related genes (*GSTM1*, *GSTP1*, *GSTO1*, *GSTT1*, and *GSTT2*), manganese SOD (*MnSOD*), and peptide methionine sulfoxide reductase (*MSRA*). Given the central role

mitochondria have in redox signaling, there is a great deal of interest in mitochondrial genes. For example, using parallel transcriptomics, proteomics, metabolomics approach, and hierarchical clustering, Prabakaran *et al.* (19) identified 59 genes related mainly to mitochondria and energy metabolism. The review by Chowdari *et al.* (8) suggests several promising candidate genes and suggestive genetic associations. For example, the associations with *NOS1*, *MnSOD*, and *MSRA*, in conjunction with the reported cellular studies and the published clinical studies of schizophrenia suggest a pathogenic role for the related protein products.

The term "proteome" was defined originally as "the study of the total set of expressed proteins by a cell, tissue or organism at a given time under a determined condition" (29). The most traditional proteomic method is a combination of two-dimensional gel electrophoresis (2DE) for protein separation and mass spectrometry (MS) for identification. This combination of technologies allows the simultaneous separation of many hundreds of proteins in a single experiment. Direct MS-based approaches have also been employed, known as shotgun proteomics or liquid chromatography-tandem MS (LC-MS/MS) which utilize distinct chromatographic separation prior to the MS stage (15). While 2DE-MS and LC-MS/MS approaches have been used to reveal the global protein expression of a given tissue, other methods such as Western blot, immunoadsorbent assay, multiple reaction monitoring MS, and multiplex immunoassay are employed commonly for validation of differentially expressed proteins. However, this method has only been implemented recently in studies of brain disorders (7). Since all of these methods have their merits and weaknesses, the combination approach is best to maximize coverage of the relevant molecular pathways.

Mitochondria produce around 95% of the energy requirements in eukaryotic cells. These organelles are highly concentrated in the brain due to the high energy demands of this tissue. As reviewed by Martins-de-Souza *et al.* (16), abnormally high mitochondrial concentrations can lead to mitochondrial disorder (4). Glucose is the key molecule for generation of cellular energy in mitochondria. Alterations in glucose homeostasis in the schizophrenia brain have been shown (10, 27). These effects also appear to be reflected in peripheral tissues such as red and white blood cells and tissues such as liver (20, 25). Thus, it has been hypothesized that the broad mitochondrial processes are affected in schizophrenia such as calcium homeostasis, neurotransmitter transport, synaptic plasticity, and exacerbate ROS production (2). Most probably, higher ROS concentrations are not properly processed in early schizophrenia patients because key processes of stress response such as the purine catabolism are disturbed (30), leading to DNA damage, impaired energy production, altered gene and protein expression and, finally, in apoptosis and cell death, together leading to faulty neuronal plasticity, and perturbed neurotransmission. Such processes may start during neurodevelopment in schizophrenia and coincide with manifestation of symptoms during early adulthood (3, 33).

A longstanding issue in the AODS research in schizophrenia has been the primacy of peripheral tissue investigation, and the relevance of peripheral findings to a brain disorder. Thus, the increasing access to the brain *in vivo* to investigate the AODS has begun to put these concerns to rest.

Matsuzawa and Hashimoto (17) review recent studies utilizing magnetic resonance spectroscopy (MRS) to investigate GSH in the intact human brain. Four different measurement sequences including double quantum coherence filtering, Mescher–Garwood-point resolved spectroscopy, stimulated echo acquisition mode, and point resolved spectroscopy have been used to evaluate the  $^1\text{H}$ -MRS measurement of GSH in the brains of patients with schizophrenia. What is apparent is that this area of investigation is in its early stages, but the findings merit further investigation.

The discovery of impaired AODS, lipid peroxidation, and other indices of oxidative stress in schizophrenia (31) offers an obvious therapeutic approach to countering the potential oxidative damage, and its clinical sequela, in the form of antioxidants. However, investigation of the therapeutic potential of antioxidants for schizophrenia symptoms has lagged the evidence that oxidative damage is associated with poorer clinical outcome. By contrast, there has been a long-standing interest in utilizing antioxidants for treatment-emergent adverse effects such as tardive dyskinesia (6). Reddy and Reddy (22) review the therapeutic use of antioxidants in schizophrenia as adjuncts to antipsychotic agents. Some of these trials have utilized a controlled design but many others are open label. More evidence is available for the use of antioxidants for treatment-related side effects, including tardive dyskinesia and metabolic syndrome. The body of the evidence to date suggests that specific antioxidants, such as N-acetyl cysteine and vitamin E, may offer meaningful benefits for patients with schizophrenia.

The remaining article of the Forum presents original data by Gysin *et al.* (11), examining the functional implications of AODS genes. They follow up on studies that have shown an association between schizophrenia and a GAG trinucleotide repeat (TNR) polymorphism in the catalytic subunit (*GCLC*) of the glutamate cysteine ligase (*GCL*), the key enzyme for GSH synthesis. They examined the effect of *GCLC* GAG TNR genotypes on plasma thiols and fibroblast GSH levels in patients with schizophrenia with either a low-risk *GCLC* GAG TNR genotype or a high-risk genotype. They found high-risk schizophrenia genotypes were characterized by altered plasma thiols and free amino acid levels that reflect a dysregulation of redox control and an increased susceptibility to oxidative stress.

Overall, there has been growing recognition of the importance of oxidative stress in the pathophysiology of schizophrenia and in treatment-related side effects. The totality of the evidence from biochemistry, metabolomics, proteomics, genetics, and *in vivo* brain imaging points to the presence of multifarious abnormalities in the AODS and redox signaling in schizophrenia. A great deal more systematic research with appropriate methodology is required before the two primary goals of this area of research are fully realized: the elucidation of the pathophysiological role of AODS and redox signaling and the promise of antioxidant therapeutics is fulfilled.

### Acknowledgments

This work was supported in part by the grants from the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory R&D (Merit Reviews and Senior Research Career Scientist Award), VA Pittsburgh Healthcare System, and

National Institute of Health (MH58141 [J.K.Y.]). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of this article. The contents of this article do not represent the views of the Department of Veterans Affairs or the United States Government.

### References

1. Bannister WH. From haemocuprein to copper-zinc superoxide dismutase: a history on the fiftieth anniversary of the discovery of haemocuprein and the twentieth anniversary of the discovery of superoxide dismutase. *Free Radic Res Commun* 5: 35–42, 1988.
2. Ben-Shachar D. The interplay between mitochondrial complex I, dopamine and Sp1 in schizophrenia. *J Neural Transm* 116: 1383–1396, 2009.
3. Ben-Shachar D and Laifenfeld D. Mitochondria, synaptic plasticity, and schizophrenia. *Int Rev Neurobiol* 59: 273–296, 2004.
4. Boekema EJ and Braun HP. Supramolecular structure of the mitochondrial oxidative phosphorylation system. *J Biol Chem* 282: 1–4, 2007.
5. Buckman TD, Kling A, Sutphin MS, Steinberg A, and Eiduson S. Platelet glutathione peroxidase and monoamine oxidase activity in schizophrenics with CT scan abnormalities: relation to psychosocial variables. *Psychiatry Res* 31: 1–14, 1990.
6. Cadet JL and Lohr JB. Possible involvement of free radicals in neuroleptic-induced movement disorders. Evidence from treatment of tardive dyskinesia with vitamin E. *Ann N Y Acad Sci* 570: 176–185, 1989.
7. Cheng TM, Lu YE, Guest PC, Rahmoune H, Harris LW, Wang L, Ma D, Stelzhammer V, Umrana Y, Wayland MT, Lió P, and Bahn S. Identification of targeted analyte clusters for studies of schizophrenia. *Mol Cell Proteomics* 9: 510–522, 2010.
8. Chowdari KV, Bamne MN, and Nimgaonkar VL. Genetic association studies of antioxidant pathway genes and schizophrenia. *Antioxid Redox Signal* 15: 2037–2045, 2011.
9. Do KQ, Cabungcal JH, Frank A, Steullet P, and Cuenod M. Redox dysregulation, neurodevelopment, and schizophrenia. *Curr Opin Neurobiol* 19: 220–230, 2009.
10. Fucetola R, Newcomer JW, Craft S, and Melson AK. Age- and dose-dependent glucose-induced increases in memory and attention in schizophrenia. *Psychiatry Res* 88: 1–13, 1999.
11. Gysin R, Kraftsik R, Boulat O, Bovet P, Conus P, Comte-Krieger E, Polari A, Steullet P, Preisig M, Teichmann T, Cuénod M, and Do KQ. Genetic dysregulation of glutathione predicts alteration of plasma thiol redox status in schizophrenia. *Antioxid Redox Signal* 15: 2003–2010, 2011.
12. Hoffer A, Osmond H, and Smythies J. Schizophrenia: a new approach. *J Ment Sci* 100: 29–45, 1954.
13. Jablensky AV and Kalaydjieva LV. Genetic epidemiology of schizophrenia: phenotypes, risk factors, and reproductive behavior. *Am J Psychiatry* 160: 425–429, 2003.
14. Lieberman JA and Koren AR. Neurochemistry and neuroendocrinology of schizophrenia, a selective review. *Schizophr Bull* 19: 371–429, 1993.
15. Link AJ, Eng J, Schieltz DM, Carmack E, Mize GJ, Morris DR, Garvik BM, and Yates JR 3rd. Direct analysis of protein complexes using mass spectrometry. *Nat Biotechnol* 17: 676–682, 1999.
16. Martins-de-Souza D, Harris LW, Guest PC, and Bahn S. The role of energy metabolism dysfunction and oxidative stress in schizophrenia revealed by proteomics. *Antioxid Redox Signal* 15: 2067–2079, 2011.

17. Matsuzawa D and Hashimoto K. Magnetic resonance spectroscopy study of the antioxidant defense system in schizophrenia. *Antioxid Redox Signal* 15: 2057–2065, 2011.
18. McGue M, Gottesman II, and Rao DC. The transmission of schizophrenia under a multifactorial threshold model. *Am J Hum Genet* 35: 1161–1178, 1983.
19. Prabakaran S, Swatton JE, Ryan MM, Huffaker SJ, Huang JT, Griffin JL, Wayland M, Freeman T, Dudbridge F, Lilley KS, Karp NA, Hester S, Tkachev D, Mimmack ML, Yolken RH, Webster MJ, Torrey EF, and Bahn S. Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stress. *Mol Psychiatry* 9: 684–697, 2004.
20. Prabakaran S, Wengenroth M, Lockstone HE, Lilley K, Leweke FM, and Bahn S. 2-D DIGE analysis of liver and red blood cells provides further evidence for oxidative stress in schizophrenia. *J Proteome Res* 6: 141–149, 2007.
21. Prilipko LL and Lideman RR. Lipid peroxidation processes as one of the factors modifying neuronal membrane-bound proteins in schizophrenia. *Vestn Akad Med Nauk SSSR* 1: 33–37, 1982.
22. Reddy R and Reddy R. Antioxidant therapeutics for schizophrenia. *Antioxid Redox Signal* 15: 2047–2055, 2011.
23. Reddy R, Sahebarao MP, Mukherjee S, and Murthy JN. Enzymes of the antioxidant system in chronic schizophrenic patients. *Biol Psychiatry* 30: 409–412, 1991.
24. Saha S, Chant D, Welham J, and McGrath J. A systematic review of the prevalence of schizophrenia. *PLoS Med* 2: e141, 2005.
25. Schwarz E, Prabakaran S, Whitfield P, Major H, Leweke FM, Koethe D, McKenna P, and Bahn S. High throughput lipidomic profiling of schizophrenia and bipolar disorder brain tissue reveals alterations of free fatty acids, phosphatidylcholines, and ceramides. *J Proteome Res* 7: 4266–4277, 2008.
26. Shirts BH and Nimgaonkar V. The genes for schizophrenia: finally a breakthrough? *Curr Psychiatry Rep* 6: 303–312, 2004.
27. Tamminga CA, Thaker GK, Buchanan R, Kirkpatrick B, Alphs LD, Chase TN, and Carpenter WT. Limbic system abnormalities identified in schizophrenia using positron emission tomography with fluorodeoxyglucose and neocortical alterations with deficit syndrome. *Arch Gen Psychiatry* 49: 522–530, 1992.
28. van Os J and Kapur S. Schizophrenia. *Lancet* 374: 635–645, 2009.
29. Wasinger VC, Cordwell SJ, Cerpa-Poljak A, Yan JX, Gooley AA, Wilkins MR, Duncan MW, Harris R, Williams KL, and Humphery-Smith I. Progress with gene-product mapping of the Mollicutes: *Mycoplasma genitalium*. *Electrophoresis* 7: 1090–1094, 1995.
30. Yao JK, Dougherty GG Jr., Reddy RD, Keshavan MS, Montrose DM, Matson WR, McEvoy J, and Kaddurah-Daouk R. Homeostatic imbalance of purine catabolism in first-episode neuroleptic-naïve patients with schizophrenia. *PLoS One* 5: e9508, 2010.
31. Yao JK and Keshavan MS. Antioxidants, redox signaling, and pathophysiology of schizophrenia: an integrative view. *Antioxid Redox Signal* 15: 2011–2035, 2011.
32. Yao JK, Leonard S, and Reddy RD. Increased nitric oxide radicals in postmortem brains from schizophrenic patients. *Schizophr Bull* 30: 923–934, 2004.
33. Yao JK, Reddy RD, and van Kammen DP. Oxidative damage and schizophrenia: an overview of the evidence and its therapeutic implications. *CNS Drugs* 15: 287–310, 2001.

Address correspondence to:

Prof. Jeffrey K. Yao

Medical Research Service

VA Pittsburgh Healthcare System

7180 Highland Drive

Pittsburgh, PA 15206

E-mail: jkyao@pitt.edu

Date of first submission to ARS Central, December 5, 2010;  
date of acceptance, January 1, 2011.

#### Abbreviations Used

2DE	= two-dimensional gel electrophoresis
AODS	= antioxidant defense system
GCLC	= catalytic subunit of glutamate cysteine ligase
GSHPx	= glutathione peroxidase
LC-MS/MS	= liquid chromatography–tandem mass spectrometry
MnSOD	= manganese superoxide dismutase
MRS	= magnetic resonance spectroscopy
MS	= mass spectrometry
MSRA	= methionine sulfoxide reductase
NO	= nitric oxide
ROS	= reactive oxygen species
SOD	= superoxide dismutase
TNR	= trinucleotide repeat



**This article has been cited by:**

1. Agnes Ernst, Dan Ma, Isabel Garcia-Perez, Tsz M. Tsang, Wolfgang Kluge, Emanuel Schwarz, Paul C. Guest, Elaine Holmes, Zoltan Sarnyai, Sabine Bahn. 2012. Molecular Validation of the Acute Phencyclidine Rat Model for Schizophrenia: Identification of Translational Changes in Energy Metabolism and Neurotransmission. *Journal of Proteome Research* **11**:7, 3704-3714. [[CrossRef](#)]
2. Joao Miguel das Neves Duarte, Anita Kulak, Mehdi Mohammad Gholam-Razaei, Michel Cuenod, Rolf Gruetter, Kim Quang Do. 2012. N-Acetylcysteine Normalizes Neurochemical Changes in the Glutathione-Deficient Schizophrenia Mouse Model During Development. *Biological Psychiatry* **71**:11, 1006-1014. [[CrossRef](#)]
3. S Schiavone, V Jaquet, S Sorce, M Dubois-Dauphin, M Hultqvist, L Bäckdahl, R Holmdahl, M Colaianna, V Cuomo, L Trabace, K-H Krause. 2012. NADPH oxidase elevations in pyramidal neurons drive psychosocial stress-induced neuropathology. *Translational Psychiatry* **2**:5, e111. [[CrossRef](#)]
4. Xiang Yang Zhang, Da Chun Chen, Mei Hong Xiu, Wei Tang, Feixue Zhang, LianJing Liu, Yuanling Chen, JiaHong Liu, Jeffrey K. Yao, Therese A. Kosten, Thomas R. Kosten. 2012. Plasma total antioxidant status and cognitive impairments in schizophrenia. *Schizophrenia Research* . [[CrossRef](#)]
5. Zhiwei Wu, Xiang Yang Zhang, Huanhuan Wang, Wei Tang, Yu Xia, FeiXue Zhang, Jiahong Liu, Ye Fu, Jianjun Hu, Yuanling Chen, Linjing Liu, Da Chun Chen, Mei Hong Xiu, Thomas R. Kosten, Jincai He. 2011. Elevated plasma superoxide dismutase in first-episode and drug naive patients with schizophrenia: Inverse association with positive symptoms. *Progress in Neuro-Psychopharmacology and Biological Psychiatry* . [[CrossRef](#)]
6. Xue Feng Li, You Lan Zheng, Mei Hong Xiu, Da Chun Chen, Thomas R. Kosten, Xiang Yang Zhang. 2011. Reduced plasma total antioxidant status in first-episode drug-naive patients with schizophrenia. *Progress in Neuro-Psychopharmacology and Biological Psychiatry* **35**:4, 1064-1067. [[CrossRef](#)]